Evaluation of aberrantly glycosylated cancer antigen 19-9 as a novel prostate cancer biomarker
Ladataan...
1.95 MB
suljettu
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
Lataukset2
Pysyvä osoite
Verkkojulkaisu
DOI
Tiivistelmä
Prostate cancer (PCa) is the most common cancer in men and the second leading cause of cancer-related mortality in men over fifty years old. The widely used PCa screening method is a prostate-specific antigen (PSA) blood test, which, however, has limited specificity. This thesis aimed to evaluate the potential of aberrantly glycosylated cancer antigen 19-9 (CA 19-9) as a novel PCa biomarker to overcome difficulties with PSA testing and to identify proteins expressed in PCa.
Time-resolved fluorescence immunoassays in which europium-doped nanoparticles were coated with different lectins were used to identify CA 19-9 glycovariants in PCa patients compared to individuals with benign prostatic hyperplasia (BPH). Additionally, lectins and anti-CA 19-9 antibody fragments were used to identify proteins from extracellular vesicles derived from PCa and BPH plasma sample pools.
The glycovariant immunoassays, which detect aberrantly glycosylated CA 19-9, combined with total-PSA values better discriminated the PCa from BPH individuals when utilizing macrophage galactose-type lectins (p = 1.2 x 10-8) as well as mannose-binding lectins (p = 1.8 x 10-8) compared to the total-PSA values alone (p = 1.8 x 10-7). Additionally, proteins bound to anti-CA 19-9 or to anti-mannose-binding lectins specific to PCa were identified. The aberrantly glycosylated CA 19-9 could be a novel PCa biomarker when combined with total-PSA values, but further studies with known disease histories are needed to confirm it.